Skip to main content
. 2021 Nov 24;12:718763. doi: 10.3389/fphar.2021.718763

FIGURE 5.

FIGURE 5

Crude prevalence of drug‐resistance mutations in people with any mutation. Note: A, NRTI-associated drug-resistance mutations. B, NRTI-associated drug-resistance mutations. C, PI-associated drug-resistance mutations. D, INI-associated drug-resistance mutations. NRTIs, nucleoside reverse transcriptase inhibitors; NNRTIs, non-nucleoside reverse transcriptase inhibitors; PIs, protease inhibitors; INIs, integrase inhibitors.